SCHEMBL21552883

SCHEMBL21552883

CN1CCN(c2nc(CCC=O)cn(-c3ccc(-c4ncccn4)cc3)c2=O)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.37
HRH4 Q9H3N8 3/20 0.36
ALDH1A1 P00352 6/20 0.35
USP2 O75604 4/20 0.35
CYP1A2 P05177 4/20 0.35
HSD17B10 Q99714 4/20 0.35
CASP1 P29466 3/20 0.35
CASP7 P55210 3/20 0.35
HIF1A Q16665 3/20 0.35
GLA P06280 2/20 0.35
CYP3A4 P08684 3/20 0.35
TLR9 Q9NR96 2/20 0.35
TSHR P16473 2/20 0.35
CYP2C9 P11712 1/20 0.35
CLK4 Q9HAZ1 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
POLB P06746 2/20 0.34
KDM4E B2RXH2 2/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23257989 0.90 ALDH1A1 (0.33) SYKALDH1A1CYP1A2TSHRCYP2C9
SCHEMBL21564783 0.88 PDE10A (0.39)
SCHEMBL21564825 0.88 ALDH1A1 (0.35) ALDH1A1USP2CYP1A2HSD17B10CASP1
SCHEMBL21553110 0.87 SLC6A7 (0.36) ALDH1A1HSD17B10TSHRL3MBTL1LMNA
SCHEMBL23258205 0.86 SYK (0.39) SYKHRH4ALDH1A1USP2CYP1A2
SCHEMBL21553146 0.86 SYK (0.40) SYKTLR9MEN1KMT2AKDM4E
SCHEMBL21552971 0.85 SYK (0.36) SYKHRH4HIF1AMEN1KMT2A
SCHEMBL21553000 0.84 MEN1 (0.40) HRH4ALDH1A1USP2CYP1A2HSD17B10
SCHEMBL21564870 0.84 GBA1 (0.41) ALDH1A1POLB
SCHEMBL21552962 0.83 TSHR (0.41) ALDH1A1TSHRMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3790867-B1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2024-03-27 EP disclosed
US-11932629-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2024-03-19 US disclosed
CN-112513020-B KDM1A inhibitors for the treatment of diseases 伊美格生物科学公司 2024-02-23 CN disclosed
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 US disclosed
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 US disclosed
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 US disclosed
US-11578059-B2 KDM1A inhibitors for the treatment of disease Imago Biosciences. Inc. (US) 2023-02-14 US disclosed
US-11578059-B2 KDM1A inhibitors for the treatment of disease Imago Biosciences. Inc. (US) 2023-02-14 US disclosed
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2021-04-22 US disclosed
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2021-04-22 US disclosed
EP-3790867-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE Imago Biosciences Inc. (US) 2021-03-17 EP disclosed
WO-2019217972-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2019-11-14 WO disclosed
WO-2019217972-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2019-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11932629-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A SYK 2651/4885HRH4 3368/4885ALDH1A1 839/4885
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A SYK 2651/4885HRH4 3368/4885ALDH1A1 839/4885
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1A, KDM1B, KDM2A SYK 2621/4885HRH4 3243/4885ALDH1A1 599/4885
US-11578059-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A SYK 2651/4885HRH4 3368/4885ALDH1A1 839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.